Sign in
ELDN Stock Price, Chart, Stats & News
Eledon Pharmaceuticals, Inc.
Save
Eledon Pharmaceuticals, Inc. (ELDN) does not currently pay a dividend.
173.09M
Market cap
–
Current P/E
5.39x
Forward P/E
ELDN chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.08% |
ROA | -19.20% |
ROE | -46.46% |
D/E | 0.00x |
Interest coverage ratio | – |
ELDN valuation
P/E | – |
P/S | – |
P/B | 1.56x |
P/CF | -3.42x |
P/FCF | -2.72x |
P/OCF | -3.42x |
PEG | -0.09x |
EV multiple | -2.73x |
About
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes.
Similar securities
Based on sector and market capitalization
Report issue